# What was lost? TX Medical Weight Loss Center

> TX Medical Weight Loss Center asks what was lost: fat and lean tissue in tirzepatide research, semaglutide weight results, physical function and regain.

**Fat, lean tissue, function**

A falling weight starts an argument for me. The composition of that loss deserves a place at the center, alongside the size of the result.

## Fat and lean mass

The SURMOUNT-1 body-composition substudy found that [roughly 75% of lost weight was fat mass and roughly 25% was lean mass](https://pubmed.ncbi.nlm.nih.gov/39996356/) in adults with obesity or overweight. Those proportions were similar in the tirzepatide and placebo groups. I had been ready to applaud the subtraction. Its contents turned out to be more interesting.

The phrase weight loss makes the direction sound settled: down is the achievement. Fat and lean tissue make the applause feel premature to me. A smaller total can be impressive while the composition of the change still deserves scrutiny. Remaining tissue interests me; so does the physical ability that accompanies it.

That curiosity gives the word center a useful job here. Put the contents of the loss in the middle of the discussion, and the questions change. How much weight moved? What made up the change? Did physical limitations improve? Those questions can lead to different answers.

## The total weight result

The large weight result earns its attention. In STEP 1, adults with overweight or obesity without diabetes had a [mean body-weight change of −14.9% with semaglutide versus −2.4% with placebo at week 68](https://pubmed.ncbi.nlm.nih.gov/33567185/). Both changes are measured from baseline.

I admire the size of that result. The separate [tirzepatide body-composition finding](https://pubmed.ncbi.nlm.nih.gov/39996356/) adds a reason to look inside a total: fat and lean mass both declined. Success has acquired an extra condition for me: knowing the contents of the subtraction, while the tirzepatide proportions still give no basis for assigning them to semaglutide.

The [weight-results page](/weight-results) puts the STEP 1 trial means beside each other and follows the longer observation.

## Physical limits and treatment burden

A separate semaglutide trial in people with obesity-related heart failure with preserved ejection fraction found [improvements in symptoms and physical limitations, alongside greater weight loss than placebo](https://pubmed.ncbi.nlm.nih.gov/37622681/). That is a useful additional result in that particular population. My concern about capability has a concrete outcome to consider there.

The discomfort also has a place in this account. In SURMOUNT-1, adults with obesity and without diabetes experienced [gastrointestinal adverse effects that were mostly mild to moderate and occurred primarily during dose escalation](https://pubmed.ncbi.nlm.nih.gov/35658024/). I still count those burdens alongside a favourable weight result.

[Physical function](/physical-function) takes up the gap between tissue measurements and capability. [Weight regain](/weight-regain) follows returning weight after tirzepatide withdrawal. [Tolerability](/tolerability) examines the burdens that accompany the desired change.

---

At TX Medical Weight Loss Center I consider what weight loss contains through published research, in an editorial collection that offers neither healthcare business services nor medical advice.